IDH1 and acute myeloid leukemia: The AGILE trial demonstrated that ivosidenib plus azacitidine improved event-free survival (EFS: hazard ratio 0.33) and overall survival (OS: median 24.0 vs 7.9 months) compared to azacitidine alone in newly diagnosed, unfit IDH1-mutant AML, establishing a chemo-sparing frontline standard (Montesinos et al., 2022).